Navigation Links
CRESTOR® Patent Upheld By US Court
Date:6/29/2010

WILMINGTON, Del., June 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Judge Farnan's subsequent entry of judgment will preclude the FDA from issuing final approvals for the defendants' Abbreviated New Drug Applications (ANDAs) prior to the expiration of the '314 patent in 2016.  

"We are pleased with the court's decision upholding the validity and enforceability of the '314 substance patent," said David Brennan, Chief Executive Officer, AstraZeneca. "The court's decision reaffirms the strength of the intellectual property protecting CRESTOR.''

Judge Farnan also held that Apotex USA was liable as a submitter and is therefore bound to the court's decision.

About the Trial

Beginning in 2007, nine generic drug manufacturers filed ANDAs along with Paragraph IV certifications of non-infringement, invalidity, or unenforceability with respect to the CRESTOR patents. AstraZeneca and Shionogi (the owner of the '314 patent) filed patent infringement suits against eight manufacturers (various parent or subsidiary entities of Apotex, Aurobindo, Cobalt, Mylan, Par, Sandoz, Sun and Teva) who had challenged the '314 substance patent. The '314 patent, which expires in 2016, covers rosuvastatin calcium, the active ingredient in CRESTOR. These suits were consolidated by order of the Judicial Panel on Multidistrict Litigation and tried in the US District Court, District of Delaware. Trial commenced on February 22, 2010 before Judge Farnan and ended on March 3, 2010.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
2. Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Tevas Generic Oral Contraceptive Gianvi™
3. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
6. Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology
7. European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent
8. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
9. Solta Medical and Alma Lasers Resolve Patent Lawsuits
10. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
11. DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections Meeting. ... Almost 10,000 physical therapists across the country are expected to attend this annual convention ... field and network with their colleagues. As in years past, HydroWorx is proud ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... ... 2016 , ... AssureVest Insurance Group, a locally owned insurance firm with offices ... raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and 3rd ... in a low-income area and has more than 60 2nd and 3rd graders with ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... metro area, celebrates the beginning of the latest charity campaign in their community ... through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... and surrounding communities by continuing it’s commitment to act as Agents of Change ... organization works closely with area homeless families to fulfill immediate needs and help ...
Breaking Medicine News(10 mins):